Aryl Hydrocarbon Hydroxylases
-
Subject Areas on Research
-
3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.
-
A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.
-
A pharmacogenetic versus a clinical algorithm for warfarin dosing.
-
A preliminary analysis of interactions between genotype, retrospective ADHD symptoms, and initial reactions to smoking in a sample of young adults.
-
Acceptance of high platelet reactivity as a risk factor: now, what do we do about it?
-
Analysis of medaka cytochrome P450 3A homotropic and heterotropic cooperativity.
-
Anthracenedione antineoplastic agent effects on drug metabolism in vitro and in vivo: relationship between structure and mechanism of inhibition.
-
Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4.
-
Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children.
-
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
-
Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa.
-
CYP1B1 knockdown does not alter synergistic developmental toxicity of polycyclic aromatic hydrocarbons in zebrafish (Danio rerio).
-
CYP1B1, MYOC, and LTBP2 mutations in primary congenital glaucoma patients in the United States.
-
CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects.
-
CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.
-
CYP2E1 G1532C, NQO1 Pro187Ser, and CYP1B1 Val432Leu polymorphisms are not associated with risk of squamous cell carcinoma of the head and neck.
-
Characterization of the effects of tebufelone on hepatic cytochromes P450 in the beagle dog.
-
Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.
-
Clinical application of cardiovascular pharmacogenetics.
-
Cloning genes that encode drug-metabolizing enzymes: developmental pharmacology and teratology.
-
Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19.
-
Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.
-
Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.
-
Cytochrome P450 2C9 plays an important role in the regulation of exercise-induced skeletal muscle blood flow and oxygen uptake in humans.
-
Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
-
Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity.
-
Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents.
-
Does race modify the association between CYP1B1 Val432Leu polymorphism and breast cancer risk? A critical appraisal of a recent meta-analysis.
-
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.
-
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
-
Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.
-
Effect of age and gender on the activity of human hepatic CYP3A.
-
Eight common genetic variants associated with serum DHEAS levels suggest a key role in ageing mechanisms.
-
Enantiomeric metabolic interactions and stereoselective human methadone metabolism.
-
Estimation of the warfarin dose with clinical and pharmacogenetic data.
-
Estrogen metabolism within the lung and its modulation by tobacco smoke.
-
Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy.
-
Expression and subcellular distribution of mouse cytochrome P1-450 mRNA as determined by molecular hybridization with cloned P1-450 DNA.
-
Fibronectin-mediated hepatocyte shape change reprograms cytochrome P450 2C11 gene expression via an integrin-signaled induction of ribonuclease activity.
-
First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
-
Genetic-based dosing in orthopedic patients beginning warfarin therapy.
-
Genome-wide association study of smoking behaviours in patients with COPD.
-
Hepatic cytochrome P-4503A (CYP3A) activity in the elderly.
-
Human halothane metabolism, lipid peroxidation, and cytochromes P(450)2A6 and P(450)3A4.
-
Human halothane reduction in vitro by cytochrome P450 2A6 and 3A4: identification of low and high KM isoforms.
-
Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4.
-
Identification and characterization of a cDNA encoding cytochrome P450 3A from the fresh water teleost medaka (Oryzias latipes).
-
Identification of an endogenous ligand that activates pregnane X receptor-mediated sterol clearance.
-
Identification, characterization, and ontogeny of a second cytochrome P450 3A gene from the fresh water teleost medaka (Oryzias latipes).
-
In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3.
-
Induction of cytochrome P(1)450 RNA and benzo[a]pyrene metabolism in primary human hepatocyte cultures with benzanthracene.
-
Induction of pulmonary and hepatic cytochrome P-450 species by coal fly ash inhalation in rats.
-
Influence of CYP2C19*2 and *3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: the results of the ACCEL-DOUBLE-2N3 study.
-
Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.
-
Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate.
-
Inhibition of coal fly ash polycyclic aromatic hydrocarbons and metals induced mixed-function oxidase activity in rat lung and liver by vitamin A and citrate.
-
Interactions between genotype and retrospective ADHD symptoms predict lifetime smoking risk in a sample of young adults.
-
Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
-
Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1.
-
Letter by Gurbel et al regarding article, "Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement".
-
Mechanism of autoinduction of methadone N-demethylation in human hepatocytes.
-
Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics.
-
Metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) by human CYP1B1 genetic variants.
-
Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes.
-
Metabolism of levo-alpha-Acetylmethadol (LAAM) by human liver cytochrome P450: involvement of CYP3A4 characterized by atypical kinetics with two binding sites.
-
Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6.
-
Molecular characterization of CYP2B6 substrates.
-
Omeprazole: a possible new candidate influencing the antiplatelet effect of clopidogrel.
-
On the occurrence of cytochrome P-450 and aryl hydrocarbon hydroxylase activity in rat brain.
-
Pharmacogenetic guidance for antiplatelet treatment.
-
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.
-
Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.
-
Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes.
-
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir.
-
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
-
Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk.
-
Role of CYP2B6 in stereoselective human methadone metabolism.
-
Role of cytochrome P4502B6 in methadone metabolism and clearance.
-
Role of cytochrome P4503A in cysteine S-conjugates sulfoxidation and the nephrotoxicity of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in rats.
-
Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
-
Screening of 16 common therapeutic drugs. Possible association with the Ah locus.
-
Screening of CYP1B1 and LTBP2 genes in Saudi families with primary congenital glaucoma: genotype-phenotype correlation.
-
Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil.
-
Single-dose disulfiram does not inhibit CYP2A6 activity.
-
Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity.
-
Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity.
-
Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes.
-
Structure-activity relationships of chlorinated benzenes as inducers of hepatic cytochrome P-450 isozymes in the rat.
-
Suppression of male-specific cytochrome P450 2c and its mRNA by 3,4,5,3',4',5'-hexachlorobiphenyl in rat liver is not causally related to changes in serum testosterone.
-
Synergistic induction of AHR regulated genes in developmental toxicity from co-exposure to two model PAHs in zebrafish.
-
Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs).
-
The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans.
-
The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity.
-
The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients.
-
The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients.
-
The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.
-
The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
-
The long and winding road to warfarin pharmacogenetic testing.
-
The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.
-
The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patient.
-
Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis.
-
Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps?
-
Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases.
-
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.
-
Use of pharmacogenetics to guide warfarin therapy.
-
Vitamins E and K induce aryl hydrocarbon hydroxylase activity in human cell cultures.
-
We need further studies for the development of "optimized antiplatelet therapy" based on ethnicity.